菜单

Perspectives

Unlocking the Potential of Biologics with Advanced Drug Product Manufacturing and Development Technologies
Apr. 09, 2026
Unlocking the Potential of Biologics with Advanced Drug Product Manufacturing and Development Technologies

As patient preferences and healthcare systems increasingly shift toward more convenient treatment options, subcutaneous (SC) administration and high‑concentration biologics have become critical enablers for next‑generation biologic medicines. However, the development and commercialization of such products remain constrained by significant challenges, including excessive viscosity and aggregation, complex integration with delivery devices, and stringent clinical‑in‑use (CIU) regulatory requirements.

 

Leveraging its comprehensive drug product (DP) development and manufacturing capabilities, WuXi Biologics has built integrated, end‑to‑end solutions to address these challenges. By combining advanced formulation strategies, device‑drug integration expertise, and robust CIU study frameworks, the company supports the efficient development of high‑concentration biologics while reducing technical risk and accelerating time to market. These solutions reflect years of accumulated DP know‑how and continuous innovation across formulation, fill‑finish, and device compatibility.

 

This article highlights a featured thought‑leadership contribution by Jeremy Guo, Senior Vice President, Head of Global Drug Product Operations Department of WuXi Biologics, published in Contract Pharma. The article discusses key challenges in high‑concentration biologics development and highlights integrated, platform‑enabled approaches to improve product quality and accelerate the commercialization of advanced biologics.

 

Click the link to read the full article:

https://www.contractpharma.com/unlocking-the-potential-of-biologics-with-advanced-drug-product-manufacturing-and-development-technologies/